Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polyneuropathy caused by chlorprothixene.

M Luisto1

  • 1Department of Neurology, Kivelä Hospital, Helsinki, Finland.

Acta Psychiatrica Scandinavica
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Fever, seizures and unconsciousness in a young woman leading to death].

Duodecim; laaketieteellinen aikakauskirja·2002
Same author

[What is a proper Finnish term for ENMG?].

Duodecim; laaketieteellinen aikakauskirja·1997
Same author

[Guidelines for the diagnosis and treatment of patients with acute ischemic stroke].

Duodecim; laaketieteellinen aikakauskirja·1996
Same author

Surgical patients with surprising laboratory data.

The British journal of clinical practice·1995
Same author

Hyperostosis and osteoarthritis in patients surviving after tetanus.

Skeletal radiology·1994
Same author

Tetanus of immunized children.

Developmental medicine and child neurology·1993

Chlorprothixene can cause toxic polyneuropathy, affecting nerves in the limbs. Symptoms improved after discontinuing the medication, indicating a reversible condition.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Antipsychotic medications are widely used in psychiatric care.
  • Chlorprothixene is a typical antipsychotic with a known side effect profile.
  • Neurological adverse effects of psychotropic drugs require careful monitoring.

Purpose of the Study:

  • To investigate the potential link between chlorprothixene use and the development of polyneuropathy.
  • To characterize the clinical and electrophysiological findings in patients experiencing neurological symptoms attributed to chlorprothixene.
  • To assess the reversibility of polyneuropathy after drug withdrawal.

Main Methods:

  • Case series involving seven chronic psychiatric patients.
  • Clinical assessment of neurological symptoms, particularly in the lower limbs.

Related Experiment Videos

  • Electroneuromyography (ENMG) to evaluate nerve conduction velocities and signs of denervation.
  • Monitoring of symptoms following cessation of chlorprothixene.

    • Main Results:

    • All seven patients developed polyneuropathy, primarily affecting lower limbs, after prolonged chlorprothixene treatment (3-24+ months) at doses of 500-1800 mg/d.
    • Electroneuromyography revealed significantly reduced or absent motor conduction velocities in peroneal nerves and signs of denervation in leg muscles (and upper limbs in 4 patients).
    • Neuropathic signs showed gradual improvement after chlorprothixene withdrawal.

    Conclusions:

    • Chlorprothixene may induce a dose-dependent and reversible toxic polyneuropathy.
    • Early identification and discontinuation of the drug are crucial for symptom resolution.
    • Further research into the neurotoxic mechanisms of chlorprothixene is warranted.